Blood-based Alzheimer's diagnosis may achieve greater accuracy by combining two complementary tau protein markers rather than relying on single biomarker approaches. This advancement could transform clinical practice by enabling more precise identification of patients whose cognitive symptoms stem from Alzheimer's pathology versus other neurodegenerative causes.
Swedish researchers demonstrated that plasma eMTBR-tau243, which reflects tau tangle burden in brain tissue, significantly improves diagnostic classification when added to established p-tau217 testing. Among patients already testing positive for p-tau217, the addition of eMTBR-tau243 enhanced identification of established Alzheimer's disease and predicted both cognitive decline trajectories and future tau accumulation. The dual-marker approach was validated across two independent cohorts spanning cognitive stages from normal function through dementia.
This represents a meaningful evolution in Alzheimer's biomarker strategy, moving beyond simple positive-negative classifications toward more nuanced disease stratification. The eMTBR-tau243 marker functions as what researchers term a "core 2 biomarker" - one that changes longitudinally after initial pathology detection, providing dynamic insight into disease progression rather than just presence. For clinical practice, this could resolve a persistent challenge: distinguishing patients whose cognitive symptoms reflect active Alzheimer's pathology from those with biomarker positivity but symptoms from other causes. The approach also addresses the reality that single biomarker thresholds often miss the complexity of Alzheimer's heterogeneity. While promising, broader validation across diverse populations and healthcare settings will be essential before routine clinical implementation.